In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
One-year outcomes of elderly patients with atrial fibrillation: snapshot data from the global noninterventional program on edoxaban treatment in routine clinical practice in atrial fibrillation
Authors : CC Wang (Taipei,TW), YH Kim (Seoul,KR), B Brueggenjuergen (Berlin,DE), R De Caterina (Pisa,IT), P Kirchhof (Birmingham,GB), BC Lee (Anyang-Si, Gyeonggi-Do,KR), P Levy (Paris,FR), H Rauer (Munich,DE), PE Reimitz (Munich,DE), M Unverdorben (Basking Ridge,US), T Yamashita (Tokyo,JP), Y Koretsune (Osaka,JP)
C.C. Wang1
,
Y.H. Kim2
,
B. Brueggenjuergen3
,
R. De Caterina4
,
P. Kirchhof5
,
B.C. Lee6
,
P. Levy7
,
H. Rauer8
,
P.E. Reimitz8
,
M. Unverdorben9
,
T. Yamashita10
,
Y. Koretsune11
,
1Chang Gung University, Department of Cardiology - Taipei - Taiwan
,
2Korea University College of Medicine, Department of Internal Medicine - Seoul - Korea (Republic of)
,
3Steinbeis-University, Head Institute for Health Economics - Berlin - Germany
,
4University of Pisa, Chair of Cardiology - Pisa - Italy
,
5University of Birmingham, Institute of Cardiovascular Sciences - Birmingham - United Kingdom
,
6Hallym University Sacred Heart Hospital - Anyang-Si, Gyeonggi-Do - Korea (Republic of)
,
7Universite Paris-Dauphine - Paris - France
,
8Daiichi Sankyo Europe GmbH - Munich - Germany
,
9Daiichi Sankyo, Inc - Basking Ridge - United States of America
,
10Cardiovascular Institute - Tokyo - Japan
,
11National Hospital Organization Osaka National Hospital - Osaka - Japan
,
Background: As populations age, prevalence of atrial fibrillation (AF) and ensuing need for oral anticoagulation increase. Benefits and risks of nonvitamin K antagonist oral anticoagulants such as edoxaban in the frail, elderly population with AF in regular clinical care is of special interest.
Purpose: Data from Global ETNA-AF capturing almost 20000 patients treated with edoxaban in Europe, Japan, and Korea/Taiwan, was analyzed to compare outcomes in patients <75 years, elderly (≥75 years), and very elderly (≥85 years) patients.
Methods: Global ETNA-AF is a multinational, multicentre, prospective, noninterventional program (EU: NCT02944019, Japan: UMIN000017011, Korea/Taiwan: NCT02951039). Demographics, baseline characteristics, and 1-year outcome data were reported for 19416 patients classified into 3 age categories.
Results: At 1-year follow-up, rates of major bleeding (including intracranial haemorrhage [ICH]) and ischaemic stroke were generally low. All-cause and CV mortality increased with age; CV mortality was a minor proportion of all-cause mortality in all age groups. Rates of major bleeding and ischaemic stroke increased slightly with age, but to a lesser extent than all-cause and CV mortality. There was no increase in the rate of ICH with age.
Conclusion: Global data from this set of unselected patients support the use of edoxaban as a safe and effective treatment in elderly and very elderly patients with AF in regular clinical care.
